Prime Medicine
Marina Lilieholm is a skilled scientist with experience in in-vitro pharmacology and sequence analytics for gene editing. Marina has held roles at Prime Medicine, Inc., Celgene, and Century Therapeutics, LLC. Marina also has experience as a Research Specialist at the University of Pennsylvania and as a Residential Assistant at Drexel University. Marina holds an Accelerated BS/MS in Biomedical Engineering from Drexel University.
This person is not in the org chart
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.